Contact Me
Subscribe
Posts
All Comments
Search
Followers
Blog Archive
- ► 2012 (246)
- ► 2011 (708)
- ► 2010 (847)
- ► 2009 (882)
About Me
- A Stuijt
- Retired South African medical journalist, ex-Sunday Times of Johannesburg.
520,000 people died in South Africa under ANC-rule
18:00 | 
Posted by
A Stuijt |
Manto and Mbeki Aids policy killed 330,000 people
Add to this figure of 330,000 lives lost to AIDS, the annual average of 43,000 violent deaths a year ( 20,000 murders plus 23,000 culpible homicides) and you will see that Mbeki's nine-and-a-half years of disastrous rule has cost the lives of at least 520,000 South Africans! Stupidity comes with a price. The ANC must be so proud!
- - -
More than 330,000 lives were lost to HIV/AIDS in South Africa from 2000 and 2005 -- only because South African ex-president Thabo Mbeki refused to implement an entirely feasible and timely antiretroviral (ARV) treatment program. This was the assertion from the Harvard School of Public Health (HSPH) in a study published online by the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
In addition, an estimated 35,000 babies were born with HIV during that same period in the country because a feasible mother-to-child transmission prophylaxis program using nevirapine (an anti-AIDS drug) also was not implemented, the authors write.
The paper estimates the consequences of the disastrous anti-treatment policies followed by the Mbeki-regime for a five-year period when neighboring countries also ramped up their HIV-prevention programmes. The paper may have broader implications for the evaluation of consequences of public health programs.
Dr. Pride Chigwedere, MD, SD, lead author of the paper, and colleagues estimated what they described as the ARV benefits lost that were attributable to Mbeki-government policies restricting or delaying the use of ARV treatment in South Africa.
- For comparison, the authors used Botswana and Namibia, neighboring countries facing epidemics of similar scale and dynamics and with similar resources per capita.
- Dr. Chigwedere led the analysis while earning his doctoral degree in immunology and infectious diseases from HSPH, graduating in June 2008. He came to HSPH from Zimbabwe, where he was a practicing physician treating AIDS patients.
South Africa is one of the countries most severely affected by the AIDS epidemic (which over the past three years has become 'Turbo-TB' because of a deadly new strain of Tuberculosis affecting these patients). The authors cite UNAIDS data that the prevalence of HIV/AIDS in the adult population is 18.8 percent, with approximately 5.5 million persons infected with HIV by the end of 2005.
Under the leadership of Thabo Mbeki, who was president of South Africa during the period examined in the paper, his government deliberately restricted use of free, donated nevirapine and also deliberately blocked Aids-treatment funds for more than a year from the Global Fund to Fight AIDS, Tuberculosis, and Malaria awarded to the South African province KwaZulu Natal, the authors recount.
- President Mbeki formally resigned in September 2008.
- The authors estimated the lost benefits of ARV drug use for two groups: AIDS patients and children born to HIV-infected mothers. The research team framed those lost benefits as "person-years," meaning the number of years of life lost due to premature death from HIV/AIDS. The team chose a limited time period for examination to estimate only the ARV benefits already lost and to avoid speculation about the future direction of ARV policies in South Africa.
Background: The pharmaceutical company Boehringer Ingelheim announced in July 2000 that it would offer nevirapine free of charge for five years for the prevention of mother-to-child transmission of HIV-1 in developing economies. South Africa restricted the availability of nevirapine to two pilot sites per province until December 2002, said Dr. Chigwedere.
The country's government launched a national program for the prevention of mother-to-child transmission in August 2003 and a national ARV treatment program in 2004. By 2005, the authors estimated, there was 23% ARV treatment coverage and less than 30% prevention of mother-to-child transmission coverage in South Africa.
- By comparison, neighboring Botswana began a program for the prevention of mother-to-child transmission in 1999 and a national ARV treatment program in 2001. Using WHO "3x5" initiative data, the authors estimated that there was 85% ARV treatment coverage in Botswana and 71% in Namibia by 2005.
- Both Botswana and Namibia achieved >70% prevention of mother-to-child transmission coverage by 2005.
To estimate the lost benefits, the research team compared the actual number of South African persons who received ARVs for treatment or for prevention of mother-to-child transmission between 2000 and 2005 with what was reasonably feasible in the country during that period. They then multiplied the difference by the average efficacy of ARV treatment or prevention of mother-to-child transmission prophylaxis.
- "The analysis is robust," said Dr. Chigwedere. "We used a transparent and accessible calculation, publicly available data, and, where we made assumptions, we explained their basis. We purposely chose very conservative assumptions and performed sensitivity analyses to test whether the results would qualitatively change if a different assumption were used."
In conclusion, the authors write: "Access to appropriate public health practice is often determined by a small number of political leaders. In the case of South Africa, many lives were lost because of a failure to accept the use of available ARVs to prevent and treat HIV/AIDS in a timely manner."
Source: Harvard School of Public Health - Wed, 22/10/2008
Labels:
